Response Biomedical Corp.

08/31/2026

No diabetes. No hypertension. No high cholesterol. No smoking history. By every standard measure, these women would be classified as low risk for cardiovascular disease.

A 30-year study of 12,530 women found otherwise. Elevated hsCRP predicted significantly higher cardiovascular risk, even when every traditional risk factor came back clear. Women with hsCRP >3 mg/L had 77% higher risk of coronary heart disease, 52% higher risk of total cardiovascular events, and 39% higher risk of stroke.

Read full article: https://lnkd.in/e5v92dND

08/24/2026

We're proud to share that our RAMP® technology is the foundation for ACTIS, a new portable device selected by the Canadian Space Agency to help assess astronauts' blood clot risk onboard the International Space Station.

Accurate diagnostics shouldn't stop at Earth's atmosphere. Through ACTIS, the CSA is exploring the potential of D-dimer detection using Response Biomedical's RAMP® technology in space and beyond.

ACTIS is scheduled to be launched and tested during CSA astronaut Joshua Kutryk's mission in 2026.

We're grateful to our team and our partners at Somagen Diagnostics for helping make this possible, and to the Canadian Space Agency for the opportunity to contribute to advancing medical care on the final frontier.

🔗 Learn more: https://www.asc-csa.gc.ca/eng/sciences/actis.asp

08/21/2026

08/19/2026

A 2026 systematic review and meta-analysis examined the association between HbA1c variability and the risk of diabetic kidney disease and diabetic retinopathy. Across 45 cohort studies involving more than 172,000 participants, greater HbA1c variability was associated with adverse renal and retinal outcomes.

These findings highlight an important consideration in diabetes management: looking at HbA1c trends over time, not just a single measurement, may provide a more complete picture of glycemic control.

Read the full study to explore what the latest evidence says about HbA1c variability and diabetic complications.

Link: https://pubmed.ncbi.nlm.nih.gov/41694560/

08/14/2026

Nos enorgullece ser parte de PROMED Day 2026!
Acompaña a nuestra Dra. Camila López, PhD, Especialista de Soporte Clínico, en su presentación "El poder de elegir: más allá del panel" — donde exploraremos cómo la flexibilidad diagnóstica con RAMP® 200 permite una atención más personalizada.

20 de agosto, 2026 · Día 2
12:05 p.m. (Centroamérica) · 1:05 p.m. (Panamá) · Evento Virtual
Regístrate gratis: https://bit.ly/4i9q0rj

Gracias a nuestro socio comercial Promed Panamá por organizar este evento en Centroamérica, Panamá y el Caribe.

07/16/2026

We're excited to be at ADLM 2026 in Anaheim!

Stop by the Response Biomedical booth to witness the launch of our new RAMP X product line, meet our team, and explore our growing portfolio of diagnostic solutions. Everything we do is guided by our core purpose: Guiding patient care when answers matter most. We look forward to seeing you there!

07/01/2026

Wishing everyone a happy and safe Canada Day! Enjoy the celebrations with family, friends, and community.

06/30/2026

Silent progression requires smarter detection.
Kidney damage often progresses without symptoms. The RAMP® X Microalbumin (MAU) test delivers rapid, reliable detection of urinary albumin — so early clues are caught before they become a crisis. Now available on RAMP Xpress.

06/29/2026

A single glucose reading tells you about today — HbA1c tells you about the last 3 months.
With just 5 µL of capillary or venous whole blood, the RAMP® X HbA1c test delivers standardized, reliable results to support confident diabetes monitoring and management. Now available on RAMP Xpress.

06/25/2026

Cardiovascular disease risk isn't always visible.
The new RAMP® X hsCRP test helps uncover low-grade inflammation with rapid, reliable results — supporting earlier cardiovascular disease risk assessment in both preventive and at-risk patient populations. Now available on RAMP Xpress.